Home >> Tag Archives: Qiagen—

Tag Archives: Qiagen—

Qiagen launches panel, software for blood cancers

Dec. 7, 2018—Qiagen launched two novel products to deliver actionable insights on a wide range of blood cancers: a workflow for the Qiagen Clinical Insight Interpret bioinformatics solution for hematological malignancies, and the QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research using the company’s GeneReader NGS System. The QIAact myeloid panel provides an integrated sample-to-insight workflow targeting ...

Read More »

Qiagen partners with DiaSorin, NeuMoDx

November 2018—Qiagen has introduced an automated, CE-marked workflow for its Quanti-Feron-TB Gold Plus Blood Collection Tubes and a novel DiaSorin Liaison Test on DiaSorin’s Liaison systems. The launch offers Liaison customers high-throughput detection with QFT-Plus as part of the system’s broad menu, and QFT-Plus users will gain an option for full automation of laboratory handling to support TB control efforts. Customers using the new latent TB detection workflow for Liaison systems will purchase the detec-tion components from DiaSorin and the blood collection tube kits from Qiagen. The test is available in Europe and other markets, with an expected U.S. release in 2019 and in China in 2020. In a separate release, Qiagen and NeuMoDx Molecular announced a strategic partnership to commercialize two fully integrated systems for automation of PCR test-ing. Under the agreement, Qiagen will initially distribute the NeuMoDx 288 (for high throughput) and NeuMoDx 96 (for mid-throughput) in Europe and other markets outside of the United States; NeuMoDx will cover the U.S.

Read More »

Qiagen joins forces with SRL to launch companion dx

October 2018—Qiagen announced a collaboration with SRL, a large clinical testing laboratory company in Japan, to prepare for introducing new companion diagnostics simultaneously with new drug approvals. The nonexclusive master collaboration agreement for clinical laboratory research services will enable rapid implementation by SRL of Qiagen’s companion diagnostic workflows upon approval of the drugs and tests by Japan’s Pharmaceuticals and Medical Devices Agency.

Read More »

Therascreen EGFR RGQ PCR kit approved as CDx

Oct. 1, 2018—Qiagen announced that the FDA has approved a PMA supplement expanding the labeling claim of the Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or an exon 21 L858R mutation.

Read More »

Qiagen partners with Health Innovation Manchester

September 2018—Qiagen announced a partnership with multiple organizations to support creating a worldwide genomics campus in Manchester, U.K., for innovation, life sciences, translational science, and molecular diagnostics. Qiagen is working with Health Innovation Manchester to bring together public, academic, and clinical resources to develop the Genomic Health Innovation Campus, anchored by Qiagen’s European Centre of Excellence for Precision Medicine and hub for diagnostics development.

Read More »